Actualités GeneDx Holdings Corporation - WGS | Actions NASDAQ

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced it will release financial results for...

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as...

GeneDx Announces Preliminary 2024 Financial Results

Expects to exceed guidance with full year 2024 revenues1 of at least $299 million Expects fourth quarter 2024 revenues1 of at least $92 million...

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a new way to provide genetic...

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

Contributed nearly one quarter of all submissions to GeneMatcher and collaborated on more than 85 peer reviewed publications in 2024 GeneDx...

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs...

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will...

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis...

GeneDx to Participate in Upcoming Investor Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will...

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering...

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx...

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx...

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical...

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77...

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

GeneDx Holdings Corporation (WGS)

Votre Hub pour des idées et discussions en direct en temps réel

WGS Actualités

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Announces Preliminary 2024 Financial Results

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx to Participate in Upcoming Investor Conference

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

GeneDx Holdings Corporation (WGS) Actualités

GeneDx Holdings Corporation (WGS)

Votre Hub pour des idées et discussions en direct en temps réel

WGS Actualités

GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Announces Preliminary 2024 Financial Results

GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients

GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx to Participate in Upcoming Investor Conference

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités